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Abstract Nerve-derived trophic factors are known to modulate
expression of acetylcholinesterase (AChE) in skeletal muscle
fibers, yet the precise identity of these factors remains elusive. In
the present study, we treated mouse C2 myotubes with calcitonin
gene-related peptide (CGRP). Compared to non-treated myo-
tubes, cell-associated AChE activity levels were decreased by
V60% after 48 h of treatment. A parallel reduction in AChE
total protein levels was also observed as determined by Western
blot analysis. The reduction in AChE activity was due to a
decrease in the levels of the G1 molecular form and to an
elimination of G4. By contrast, levels of secreted AChE remained
unchanged following CGRP treatment. Finally, the overall
decrease in AChE activity was accompanied by a reduction in
AChE transcripts which could not be attributed to changes in the
transcriptional rate of the ACHE gene.
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1. Introduction
Several lines of evidence indicate that interactions between
motoneurons and their target muscle ¢bers regulate expres-
sion of acetylcholinesterase (AChE) in muscle tissue (for re-
view see [1]). Although previous studies have shown that
nerve-evoked electrical activity is a key regulator of AChE
in muscle, it appears that nerve-derived trophic factors also
play a signi¢cant role. In earlier studies for instance, nerve
extracts applied to cultures of denervated muscle ¢bers were
shown to maintain total AChE activity [2] whereas disruption
of axonal transport with colchicine reduced AChE activity
within muscle ¢bers [3]. In more recent reports, application
of tetrodotoxin onto the sciatic nerve, which abolishes nerve
action potentials without a¡ecting axonal transport, was
shown to lead to lesser reductions in both AChE activity
and transcript levels as compared to the e¡ects induced by
denervation [4]. Taken together, these ¢ndings demonstrate
the importance of nerve-derived molecules in directing
AChE expression at the neuromuscular junction. Nonetheless,
our current knowledge regarding the identity of speci¢c nerve-
derived trophic factors regulating AChE expression in muscle
as well as the mechanisms by which they act is currently
lacking.
Numerous studies focusing on the acetylcholine receptor
(AChR) have also highlighted the role of both nerve-derived
electrical activity and trophic substances in regulating expres-
sion of the genes encoding the various AChR subunits in
synaptic versus extrasynaptic compartments of muscle ¢bers
(for reviews see [5,6]). In particular, the calcitonin gene-related
peptide (CGRP) has been shown to a¡ect markedly expres-
sion of AChR in cultured myotubes [7^9] (for review see [6]).
We therefore hypothesized in the present study that this factor
may also regulate expression of AChE in mammalian muscle
¢bers, particularly since it was demonstrated recently that
CGRP increased AChE mRNA expression in chick myotubes
[10,11].
2. Materials and methods
2.1. C2 cell cultures and CGRP treatment
C2 cells were plated on Matrigel- (Collaborative Biomedical Prod-
ucts, Bedford, MA) coated 60 mm culture dishes and grown at 37‡C
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) (Life Sciences/Gib-
co; Burlington, Ont.) containing 10% fetal bovine serum and L-gluta-
mine. When myoblasts became con£uent, the growth medium was
replaced with di¡erentiation medium containing low serum. Five
days after plating, myotubes were treated with rat CGRP (Sigma,
St. Louis, MO) or an equal volume of sterile vehicle solution for 48
h. Since similar e¡ects on AChE expression were observed with
CGRP doses of 0.01, 0.05, 0.1 and 1 WM, we chose to treat cultured
myotubes with 0.1 WM because several previous studies have in fact
used this particular dose (see for example [7,10]). Following the ¢rst
24 h, the medium was collected and replaced with fresh di¡erentiation
medium containing either CGRP or vehicle solution.
To assess AChE activity secreted from vehicle- and CGRP-treated
myotubes, diisopropyl £uorophosphate (DFP; Sigma)-treated horse
serum was used to prepare the di¡erentiation medium. Endogenous
serum AChE was inactivated by incubating the horse serum with DFP
for 48 h then allowing the DFP to degrade for 10 days.
2.2. Extraction and analysis of acetylcholinesterase enzyme activity
Vehicle- and CGRP-treated myotubes were homogenized for 30 s
with a Polytron set at low speed in 1 ml of high-salt detergent bu¡er
containing anti-proteolytic agents: 10 mM tris(hydroxymethyl)-ami-
nomethane (Tris)-HCl (pH 7.0), 10 mM EDTA, 1 M NaCl, 1% Triton
X-100, 2.5 mg/ml aprotinin and 1 mg/ml bacitracin [12]. Samples were
then centrifuged at 14 000 rpm for 15 min. The medium was collected
after each 24 h period of vehicle or CGRP treatment. Samples were
spun at 2000 rpm to remove cell debris. Following centrifugation, the
supernatants obtained from the cell extracts and media were stored at
380‡C.
Total AChE activity was determined using the spectrophotometric
method of Ellman et al. [13] as described elsewhere [12,14]. The ac-
tivity was measured in the presence of the non-speci¢c cholinesterase
inhibitor tetraisopropylpyrophosphoramide (iso-OMPA). The total
amount of protein present in the extracts was determined by the
bicinchoninic acid assay (BCA; Pierce Laboratories). AChE molecu-
lar form pro¢les were determined by sedimentation analysis according
to Jasmin and Gisiger [12]. Creatine kinase activity was assayed using
a commercially available kit (Sigma).
2.3. Western blot analysis
Protein extracts from cultured myotubes were denatured at 100‡C
for 5 min in a bu¡er containing 0.5% sodium dodecyl sulfate (SDS),
0.5% Triton, 1 mM phenylmethylsulfonyl £uoride, aprotinin (0.2
U/ml), 0.01 M Tris-HCl (pH 8.0), 0.14 M NaCl and 0.025% NaN3.
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Samples were separated by SDS-PAGE in a mini-PROTEAN II Cell
apparatus (Bio-Rad, Richmond, CA). After separation, proteins were
electroblotted onto a PVDF membrane (Schleicher and Schuell,
Keene, NH) and the membrane was then incubated with a mouse
monoclonal AChE antibody (Transduction Laboratories, Lexington,
KY; 1:2500 dilution) for 1 h followed by a second incubation with a
horseradish peroxidase-conjugated secondary antibody for 30 min
(1:3000 dilution). The band corresponding to AChE (68 kDa) was
visualized by chemiluminescence using an ECL kit (NEN Life Science
Products, Boston, MA) and its intensity was quantitated with the
ImageQuant software program (Molecular Dynamics, Sunnyvale,
CA).
2.4. Reverse transcription and polymerase chain reaction
Total RNA was isolated from myotubes using 2 ml of Trizol (Gib-
co) per dish. Following isopropanol precipitation, the ¢nal pellets
were washed with 70% ethanol, air-dried and resuspended in
RNase-free water. RNA samples were adjusted to a ¢nal concentra-
tion of 80 ng/Wl using a GeneQuant II RNA/DNA spectrophotometer
(Pharmacia). Reverse transcription (RT) of 2 Wl of each RNA sample
was carried out as previously described [4]. Negative control samples
were also prepared by substituting the 2 Wl of input RNA by the same
volume of RNase-free water.
cDNAs encoding the AChE T subunit and ribosomal RNA (rRNA)
were ampli¢ed using the polymerase chain reaction (PCR) as de-
scribed in detail elsewhere [4,15]. Primers for mouse AChE (5P-
CTGGGGTGCGGATCGGTGTACCCC, cDNA nucleotides 1175^
1198; 3P-TCACAGGTCTGAGCAGCGCTCCTG, cDNA nucleo-
tides 1821^1844) and S12 rRNA (5P-GGAAGGCATAGCTGCTGG,
cDNA nucleotides 65^82; 3P-CCTCGATGACATCCTTGG, cDNA
nucleotides 415^432) were synthesized on the basis of available se-
quences [16,17]. For these experiments, several precautions were taken
to minimize sample contamination and mRNA degradation (see [18])
and to ensure that all measurements were taken within the linear
phase of ampli¢cation (see [4,15,19]). Following ampli¢cation
(AChE, 35 cycles; rRNA, 28 cycles), PCR reaction products were
visualized on a 1% ethidium bromide-stained agarose gel. Quantitative
PCR experiments were performed by separating PCR products on a
Vistragreen (Amersham; Arlington Heights, IL)-stained agarose gel
and by scanning the gel with a Storm PhosphorImager (Molecular
Dynamics, Sunnyvale, CA). The intensity of the AChE bands was
determined and standardized according to the rRNA PCR products
using the accompanying ImageQuant software program.
2.5. Nuclear run-on analysis
Nuclear run-on assays were performed using a procedure described
elsewhere [20]. Following in vitro transcription and RQ1 DNase
(Promega) treatment, labelled RNA was isolated using Trizol and
hybridized for 48 h at 42‡C with 10 Wg of linearized AChE (2 kb)
and L-actin (2 kb) cDNAs and genomic DNA immobilized on Gene-
screen Plus nylon membrane (DuPont). Following hybridization,
membranes were washed thoroughly (1USSC, 0.1% SDS) at 42‡C,
and exposed for autoradiography. The intensity of the signals was
quanti¢ed with a Storm PhosphorImager (Molecular Dynamics).
The signals corresponding to AChE were standardized relative to
the L-actin signal.
2.6. Statistical analysis
Paired Student’s t-tests were performed to determine the impact of
CGRP treatment on AChE expression. The level of signi¢cance was
set at P6 0.05. Data are expressed as means þ S.E.M. throughout.
The pattern of AChE molecular forms displayed in Figs. 1 and 3
are representative examples.
3. Results
As shown in Fig. 1A, total AChE activity expressed per
culture dish was reduced by approximately 60% (P6 0.05)
after CGRP treatment. AChE activity expressed per mg of
extracted proteins was also reduced to the same extent follow-
ing CGRP application. Similarly, primary cultures of mouse
myotubes treated with CGRP also displayed a signi¢cant re-
duction in AChE expression (data not shown). Consistent
with these activity data, Western blot analysis of extracts
from vehicle- and CGRP-treated myotubes also revealed a
signi¢cant reduction (control (CTL) = 9244 þ 296, n = 3;
CGRP = 5037 þ 407, n = 3; arbitrary units; P6 0.05) in
AChE protein levels (Fig. 2).
Velocity sedimentation analysis of extracts obtained from
vehicle- and CGRP-treated myotubes revealed that the distri-
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Fig. 1. E¡ects of CGRP on cell-associated AChE activity and mo-
lecular forms in myotubes. A: Analysis of AChE activity per culture
dish measured from protein extracts isolated from vehicle- (control;
CTL, n = 7 independent cell cultures) and CGRP-treated (CGRP,
n = 7 independent cell cultures) cultured myotubes. B: Representa-
tive examples of AChE molecular form pro¢les obtained from ve-
hicle- (circles) and CGRP-treated (triangles) myotubes. C: Activity
of AChE molecular forms in vehicle-control (open bars) and
CGRP-treated (closed bars) myotubes. Asterisks denote signi¢cant
di¡erences (P6 0.05).
C. Boudreau-LarivieØre, B.J. Jasmin/FEBS Letters 444 (1999) 22^26 23
bution of AChE molecular forms was altered following
CGRP treatment (Fig. 1B). Consistent with a recent report
[21], we observed in control myotubes an elevated level of G1
as well as a signi¢cant peak of G4. By contrast, levels of G1
were reduced considerably following CGRP treatment where-
as the amount of tetramer was virtually eliminated (Fig. 1C).
This latter e¡ect of CGRP on G4 levels appeared as a speci¢c
downregulation since even prolonged incubation (up to 24 h)
of extracts from CGRP-treated myotubes with Ellman’s assay
bu¡er failed to yield detectable G4 peaks.
We next determined whether AChE activity and molecular
forms in the media were also a¡ected by CGRP. Samples of
di¡erentiation medium collected after the ¢rst and second 24 h
treatment periods were therefore assayed. Interestingly, total
activity of the secreted enzyme remained unaltered in CGRP-
treated myotubes in comparison to vehicle-treated cells (Fig.
3A; Ps 0.05). As previously observed (see for instance [22]), a
large proportion of secreted AChE was contributed by the
globular tetramer, and CGRP did not modify this pattern
of molecular form secretion (Fig. 3B,C). When total AChE
activity was tabulated per culture dish, thus accounting for
both cell-associated and secreted enzyme, we found that
CGRP treatment downregulated AChE activity by approxi-
mately 20%. Creatine kinase levels, used as a marker of di¡er-
entiation, were found to be nearly identical in vehicle- versus
CGRP-treated myotubes (CTL = 5.07 þ 0.97, n = 6; CGRP =
5.32 þ 1.29, n = 7; arbitrary units; Ps 0.05) thereby ruling
out the possibility that the observed reductions in AChE levels
in response to CGRP were due to di¡erences in the stage of
myotube di¡erentiation.
Finally, we also examined whether the decrease in AChE
observed following CGRP treatment was accompanied by a
concomitant reduction in the abundance of its mRNA. As
shown in Fig. 4A,B, AChE transcript levels were reduced by
approximately 30% (P6 0.05) following CGRP treatment.
This decrease in AChE transcript levels is therefore in good
agreement with the overall reduction in AChE enzymatic ac-
tivity (cell-associated plus secreted; see above). Additional
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Fig. 2. E¡ects of CGRP on AChE protein levels as determined by
Western blot analysis. A: Shows representative examples of the im-
munoreactive 68 kDa AChE protein from vehicle-control (CTL)
and CGRP-treated myotube extracts. B: PVDF membranes stained
with Ponceau S which reveals that similar levels of proteins were
loaded in each lane.
Fig. 3. E¡ects of CGRP on AChE activity and molecular forms se-
creted in the media. A: Analysis of total secreted AChE activity fol-
lowing the ¢rst (1) and second (2) 24 h period of vehicle (open
bars; n = 4 independent cell cultures) or CGRP (closed bars; n = 4
independent cell cultures) treatment. B: Representative examples of
molecular form pro¢les obtained from the media of vehicle- (circles)
and CGRP- (triangles) treated myotubes. C: Activity of AChE mo-
lecular forms in vehicle- (open bars) and CGRP-treated (closed
bars) myotubes.
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experiments revealed that this reduction in AChE mRNA
levels was not due to detectable changes in the transcriptional
activity of the ACHE gene (Fig. 4C; CGRP 108% þ 13 of
control; n = 3; Ps 0.05) suggesting that CGRP likely exerts
its e¡ects at the post-transcriptional level.
4. Discussion
CGRP is a neuropeptide expressed by spinal cord motor
neurons that has received considerable attention recently for
its potential function at the neuromuscular junction (for re-
view see [6]). Until now however, the focus of most studies has
been to characterize the role of CGRP in the regulation of
AChR expression. For instance, CGRP has been shown to
increase the number of cell surface AChR by approximately
1.5-fold [8]. In addition, CGRP selectively increases the level
of transcripts encoding the AChR K-subunit by approximately
3-fold [7,9]. In the present investigation, we demonstrate that
CGRP also exerts trophic e¡ects on AChE expression by re-
ducing enzyme activity as well as the abundance of AChE
transcripts in mouse myotubes.
Modulations in AChE enzyme activity has been shown pre-
viously to correlate well with changes in AChE immunoreac-
tivity in mammalian tissue. For instance, analysis of rat de-
nervated muscle revealed a parallel reduction in both AChE
activity and AChE protein levels [23]. Consistent with these
¢ndings, our data show a similar reduction in AChE activity
and AChE protein levels in CGRP-treated cultured myotubes.
Similarly, correlations between modi¢cations in AChE en-
zyme activity and mRNA levels have also been reported. Fol-
lowing denervation of the rat extensor digitorum longus
muscle for example, AChE activity is downregulated by 90%
while AChE transcripts undergo a 10-fold reduction [4] (see
also [19]). For these reasons, we hypothesized that the de-
crease in total AChE enzyme activity seen in response to
CGRP treatment would be parallelled by a similar reduction
in AChE transcript levels. Our ¢ndings support such a corre-
lation.
In attempts to gain insight into the molecular mechanisms
underlying these reductions in AChE mRNA levels, we per-
formed run-on assays with nuclei isolated from control and
CGRP-treated myotubes. Within the range of sensitivity of
this assay, we failed to observe any signi¢cant change in the
rate of transcription of the ACHE gene with CGRP treat-
ment. Although there is evidence indicating that CGRP reg-
ulates transcription of di¡erent genes via the cAMP pathway,
the contribution of this signalling cascade in the regulation of
mRNA stability has also been documented [24^26]. Our re-
sults, in fact, ¢t nicely with the recent observations showing
that stability of existing transcripts is the primary mechanism
by which AChE mRNA levels are controlled in di¡erentiating
myotubes [27], neurons [28] and hematopoietic cells [29] main-
tained in culture. Taken together, these data indicate, there-
fore, that CGRP likely exerts its e¡ects on AChE expression
at the post-transcriptional level.
Analysis of AChE molecular forms further indicated that
CGRP exerts its e¡ects on the pattern of molecular forms
expressed by these cultured myotubes. More speci¢cally,
CGRP signi¢cantly reduced the levels of G4 in agreement
with recent in vivo studies [30,31]. Since CGRP also reduced
the amount of G1, the absence of G4 could therefore imply
that CGRP simply downregulates translation of G1 catalytic
precursors necessary for the assembly of the tetramer. Analy-
sis of the secreted forms of the enzyme, however, clearly dem-
onstrates that CGRP-treated myotubes are still capable of
assembling tetramers destined for secretion thereby indicating
that the reduction of the cell-associated G4 pool represents a
speci¢c e¡ect.
Previous studies have provided compelling evidence that in
skeletal muscle, levels of G4 are regulated independently from
the other molecular forms [12,32,33]. These studies have dem-
onstrated in fast muscle, the presence of a separate pool of G4
which can be increased substantially in response to high-fre-
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Fig. 4. E¡ects of CGRP on AChE mRNA levels in cultured mouse
myotubes. A: Examples of ethidium bromide-stained agarose gels
displaying AChE and rRNA PCR products from vehicle- (control;
C) and CGRP-treated (T) samples. Left lane is the 100 bp molecu-
lar mass marker (Gibco, BRL). B: Quantitation of AChE mRNA
levels in vehicle- (control, C; n = 5 independent cell cultures) and
CGRP-treated (T; n = 5 independent cell cultures) myotubes stand-
ardized to rRNA. Asterisk denotes a signi¢cant di¡erence
(P6 0.05). C: E¡ects of CGRP on the transcriptional rate of the
ACHE gene in cultured myotubes. This representative run-on assay
was performed with nuclei isolated from vehicle- (control; C) and
CGRP-treated (T) cultured myotubes. See text for quantitation.
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quency neuromuscular activation. Such speci¢c regulation
has, in turn, led to the suggestion that the AChE tetramer
ful¢ls a function altogether distinct from that assumed by
the synaptic forms of AChE (see for instance [12]). Speci¢-
cally, it has been suggested that G4 may be responsible for the
hydrolysis of excess acetylcholine released during high-fre-
quency activation thereby preventing desensitization of the
AChR. Interestingly, CGRP has previously been shown to
directly increase the rate of desensitization of the AChR by
modulating its phosphorylation status [34,35]. CGRP may
therefore exert its e¡ects both directly and indirectly by phos-
phorylating AChR and reducing G4 levels, respectively, in
order to ultimately increase the rate of AChR desensitization
thereby modifying the e⁄cacy of neurotransmission.
Although the physiological relevance of increased AChR de-
sensitization may be unclear, it appears reasonable to envisage
that desensitization at the neuromuscular junction may pro-
vide a myoprotective mechanism necessary during periods of
elevated phasic neuromuscular activity.
In a recent study, the e¡ects of CGRP on AChE expression
were also examined in cultured chick myotubes [10,11]. In this
latter study, levels of AChE transcripts increased approxi-
mately 3-fold following CGRP treatment with no change in
AChE activity. These data which stand in contrast to the
results of the present investigation, are not entirely unexpected
especially if we consider the dramatic di¡erences already re-
ported concerning the e¡ects of muscle denervation on AChE
expression in rodent versus chick. Speci¢cally, whereas AChE
activity levels are reduced substantially in denervated rat
muscle, enzyme activity in avian muscle appears to increase
[1]. Taken together with our current results, these ¢ndings
provide further evidence that AChE levels in muscle are di¡er-
entially regulated in response to the in£uence of neural factors
in small rodents versus avian species.
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